197 related articles for article (PubMed ID: 37097393)
1. Diagnostic performance of RASSF1A and SHOX2 methylation combined with EGFR mutations for differentiation between small pulmonary nodules.
Ji XY; Li H; Chen HH; Lin J
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8557-8571. PubMed ID: 37097393
[TBL] [Abstract][Full Text] [Related]
2. Association of the SHOX2 and RASSF1A methylation levels with the pathological evolution of early-stage lung adenocarcinoma.
Zhao J; Lu Y; Ren X; Bian T; Feng J; Sun H; Liu L; She B; Liu Y; Ke H
BMC Cancer; 2024 Jun; 24(1):687. PubMed ID: 38840077
[TBL] [Abstract][Full Text] [Related]
3. Combined Methylation of
Zhong Q; Wang Y; Liang C; Wei F; She B
Discov Med; 2023 Oct; 35(178):845-852. PubMed ID: 37811622
[TBL] [Abstract][Full Text] [Related]
4. Genetic and epigenetic alterations of the EGFR and mutually independent association with BRCA1, MGMT, and RASSF1A methylations in Vietnamese lung adenocarcinomas.
Nguyen QN; Vuong LD; Truong VL; Ta TV; Nguyen NT; Nguyen HP; Chu HH
Pathol Res Pract; 2019 May; 215(5):885-892. PubMed ID: 30723053
[TBL] [Abstract][Full Text] [Related]
5. The Diagnostic Potential of
Gao H; Yang J; He L; Wang W; Liu Y; Hu Y; Ge M; Ding J; Ye Q
Front Oncol; 2022; 12():849024. PubMed ID: 35837113
[TBL] [Abstract][Full Text] [Related]
6. Signaling pathways and clinical application of RASSF1A and SHOX2 in lung cancer.
Li N; Zeng Y; Huang J
J Cancer Res Clin Oncol; 2020 Jun; 146(6):1379-1393. PubMed ID: 32266538
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of exfoliated tumor cells combined with DNA methylation in bronchoalveolar lavage fluid for lung cancer.
Lu H; Lin D
Medicine (Baltimore); 2023 Sep; 102(36):e34955. PubMed ID: 37682182
[TBL] [Abstract][Full Text] [Related]
8. Analysis of SHOX2 methylation as an aid to cytology in lung cancer diagnosis.
Ilse P; Biesterfeld S; Pomjanski N; Wrobel C; Schramm M
Cancer Genomics Proteomics; 2014; 11(5):251-8. PubMed ID: 25331797
[TBL] [Abstract][Full Text] [Related]
9. Validation of the SHOX2/PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease.
Weiss G; Schlegel A; Kottwitz D; König T; Tetzner R
J Thorac Oncol; 2017 Jan; 12(1):77-84. PubMed ID: 27544059
[TBL] [Abstract][Full Text] [Related]
10. A prediction model based on DNA methylation biomarkers and radiological characteristics for identifying malignant from benign pulmonary nodules.
Xing W; Sun H; Yan C; Zhao C; Wang D; Li M; Ma J
BMC Cancer; 2021 Mar; 21(1):263. PubMed ID: 33691657
[TBL] [Abstract][Full Text] [Related]
11. DNA Methylation Analysis of the SHOX2 and RASSF1A Panel in Bronchoalveolar Lavage Fluid for Lung Cancer Diagnosis.
Zhang C; Yu W; Wang L; Zhao M; Guo Q; Lv S; Hu X; Lou J
J Cancer; 2017; 8(17):3585-3591. PubMed ID: 29151944
[No Abstract] [Full Text] [Related]
12. DNA Methylation Analysis of the
Zhang N; Liu Z; Li K; Xing X; Long C; Liu F; She B; Che N
J Oncol; 2023; 2023():5888844. PubMed ID: 36691467
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the comprehensive diagnosis efficiency of lung cancer, including measurement of SHOX2 and RASSF1A gene methylation.
Liu J; Bian T; She B; Liu L; Sun H; Zhang Q; Zhu J; Zhang J; Liu Y
BMC Cancer; 2024 Mar; 24(1):282. PubMed ID: 38429660
[TBL] [Abstract][Full Text] [Related]
14. [DNA methylation detection of SHOX2 and PTGER4 in plasma contributes to differential diagnosis of pulmonary nodule patients].
Chu X; Zhao W; Wang B
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2019 Apr; 35(4):357-361. PubMed ID: 31167696
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of unmethylated RASSF1A on disease progression in non-small cell lung cancer patients receiving pemetrexed-based chemotherapy.
Deng Q; Su B; Ji X; Fang Q; Zhou S; Zhou C
Cancer Biomark; 2020; 27(3):313-323. PubMed ID: 31839603
[TBL] [Abstract][Full Text] [Related]
16. A Novel Diagnosis Method Based on Methylation Analysis of SHOX2 and Serum Biomarker for Early Stage Lung Cancer.
Huang W; Huang H; Zhang S; Wang X; Ouyang J; Lin Z; Chen P
Cancer Control; 2020; 27(1):1073274820969703. PubMed ID: 33167712
[TBL] [Abstract][Full Text] [Related]
17. Short stature homeobox 2 methylation as a potential noninvasive biomarker in bronchial aspirates for lung cancer diagnosis.
Ni S; Ye M; Huang T
Oncotarget; 2017 Sep; 8(37):61253-61263. PubMed ID: 28977861
[TBL] [Abstract][Full Text] [Related]
18. Performance of SHOX2 and RASSF1A methylation assay in supernatants and matched cell pellets for the diagnosis of malignant pleural effusion.
Zhang N; Li Y; Zhang H; Dong Y; Zhang C; Du W; Long C; Xing X; Li K; Liu Z; Chen X; Zhang L; Xu F; Fu Y; Tan J; She B; Che N
Clin Chim Acta; 2024 Jan; 553():117699. PubMed ID: 38072300
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of SHOX2, RASSF1A gene methylation combined with CEA level detection in malignant pleural effusion.
Chen S; Huang K; Zou L; Chen L; Hu P
BMC Pulm Med; 2023 May; 23(1):160. PubMed ID: 37158875
[TBL] [Abstract][Full Text] [Related]
20. The combination of SHOX2 and RASSF1A DNA methylation had a diagnostic value in pulmonary nodules and early lung cancer.
Xie B; Dong W; He F; Peng F; Zhang H; Wang W
Oncology; 2024 Jan; ():. PubMed ID: 38262380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
